onger-term effects of peanut consumption on brain function in older men and women.

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 32

Inclusion Criteria

- Aged between 60-75 years
- BMI between 20-35 kg/m2
- Fasting plasma glucose < 7.0 mmol/L
- Fasting serum total cholesterol < 8.0 mmol/L
- Fasting serum triacylglycerol < 4.5 mmol/L
- Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg
- Stable body weight (weight gain or loss < 3 kg in the past three months)
- Willingness to give up being a blood donor from 8 weeks before the start of
the study, during the study and for 4 weeks after completion of the study
- No difficult venipuncture as evidenced during the screening visit

Exclusion Criteria

- Allergy or intolerance to nuts
- Left handedness
- Current smoker, or smoking cessation < 12 months
- Diabetic patients
- Familial hypercholesterolemia
- Abuse of drugs
- More than 3 alcoholic consumptions per day
- Use of nuts or dietary supplements known to interfere with the main outcomes
as judged by the principal investigators
- Use medication to treat blood pressure, lipid or glucose metabolism
- Use of an investigational product within another biomedical intervention
trial within the previous 1-month
- Severe medical conditions that might interfere with the study, such as
epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive
pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and
rheumatoid arthritis
- Active cardiovascular disease like congestive heart failure or cardiovascular
event, such as an acute myocardial infarction or cerebrovascular accident
- Contra-indications for MRI imaging (e.g. pacemaker, surgical clips/material
in body, metal splinter in eye, claustrophobia)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>At baseline, first anthropometric measurements will be performed and blood<br /><br>pressure will be determined. In addition, a fasting blood sample will be drawn.<br /><br>Another fasting blood sample will be drawn at eight weeks, while participants<br /><br>have to attend the research facilities to perform follow-up measurements after<br /><br>sixteen weeks. The primary endpoint is the difference at follow-up in the<br /><br>cerebral blood flow response before and after intranasal insulin administration<br /><br>between interventions. </p><br>

Secondary Outcome Measures